Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat in Adolescents and Adults With Sickle Cell Disease
NCT06612268Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing Etavopivat with Placebo (2 arms). Primary endpoint: Number of adjudicated Vaso-occlusive crisis (VOC) events with a medical contact at 52 weeks. Started Feb 2025; status: recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06612268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612268.